India, Oct. 9 -- image credit- shutterstock

Thermo Fisher Scientific, the world leader in serving science, has introduced a new laboratory developed test for post-transplant biopsy assessment designed to improve the detection of lung transplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment.

Due to the significant risk of rejection, lung transplant recipients often require routine biopsies to monitor the health of their new lungs. Yet, when assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a diagnosis of acute rejection.

Thermo Fisher's new Molecular Microscope(R) Diagnostic System for Lung (MMDx(R) Lung) leverages ...